281 related articles for article (PubMed ID: 28193878)
1.
Panebianco F; Kelly LM; Liu P; Zhong S; Dacic S; Wang X; Singhi AD; Dhir R; Chiosea SI; Kuan SF; Bhargava R; Dabbs D; Trivedi S; Gandhi M; Diaz R; Wald AI; Carty SE; Ferris RL; Lee AV; Nikiforova MN; Nikiforov YE
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2307-2312. PubMed ID: 28193878
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Characteristics of Thyroid Nodules Positive for the
Morariu EM; McCoy KL; Chiosea SI; Nikitski AV; Manroa P; Nikiforova MN; Nikiforov YE
Thyroid; 2021 Aug; 31(8):1212-1218. PubMed ID: 33487086
[No Abstract] [Full Text] [Related]
3. IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis.
Peixoto Lira RC; Fedatto PF; Marco Antonio DS; Leal LF; Martinelli CE; de Castro M; Tucci S; Neder L; Ramalho L; Seidinger AL; Cardinalli I; Mastellaro MJ; Yunes JA; Brandalise SR; Tone LG; Rauber Antonini SR; Scrideli CA
Endocr Relat Cancer; 2016 Jun; 23(6):481-93. PubMed ID: 27185872
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
6. RET rearrangements are actionable alterations in breast cancer.
Paratala BS; Chung JH; Williams CB; Yilmazel B; Petrosky W; Williams K; Schrock AB; Gay LM; Lee E; Dolfi SC; Pham K; Lin S; Yao M; Kulkarni A; DiClemente F; Liu C; Rodriguez-Rodriguez L; Ganesan S; Ross JS; Ali SM; Leyland-Jones B; Hirshfield KM
Nat Commun; 2018 Nov; 9(1):4821. PubMed ID: 30446652
[TBL] [Abstract][Full Text] [Related]
7. Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.
Suvasini R; Shruti B; Thota B; Shinde SV; Friedmann-Morvinski D; Nawaz Z; Prasanna KV; Thennarasu K; Hegde AS; Arivazhagan A; Chandramouli BA; Santosh V; Somasundaram K
J Biol Chem; 2011 Jul; 286(29):25882-90. PubMed ID: 21613208
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications.
Belharazem D; Magdeburg J; Berton AK; Beissbarth L; Sauer C; Sticht C; Marx A; Hofheinz R; Post S; Kienle P; Ströbel P
J Gastroenterol; 2016 Oct; 51(10):971-84. PubMed ID: 26984550
[TBL] [Abstract][Full Text] [Related]
9. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway.
Werner H; Meisel-Sharon S; Bruchim I
Mol Cancer; 2018 Feb; 17(1):28. PubMed ID: 29455671
[TBL] [Abstract][Full Text] [Related]
11. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.
Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L
Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918
[No Abstract] [Full Text] [Related]
12. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
Tognon CE; Rafn B; Cetinbas NM; Kamura T; Trigo G; Rotblat B; Okumura F; Matsumoto M; Chow C; Davare M; Pollak M; Mayor T; Sorensen PH
J Biol Chem; 2018 Aug; 293(32):12502-12515. PubMed ID: 29903916
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
14. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of
Mancarella C; Pasello M; Manara MC; Toracchio L; Sciandra EF; Picci P; Scotlandi K
Front Endocrinol (Lausanne); 2018; 9():178. PubMed ID: 29731738
[TBL] [Abstract][Full Text] [Related]
15. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
[No Abstract] [Full Text] [Related]
16. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.
Pappano WN; Jung PM; Meulbroek JA; Wang YC; Hubbard RD; Zhang Q; Grudzien MM; Soni NB; Johnson EF; Sheppard GS; Donawho C; Buchanan FG; Davidsen SK; Bell RL; Wang J
BMC Cancer; 2009 Sep; 9():314. PubMed ID: 19732452
[TBL] [Abstract][Full Text] [Related]
17. The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.
Sanderson MP; Hofmann MH; Garin-Chesa P; Schweifer N; Wernitznig A; Fischer S; Jeschko A; Meyer R; Moll J; Pecina T; Arnhof H; Weyer-Czernilofsky U; Zahn SK; Adolf GR; Kraut N
Mol Cancer Ther; 2017 Oct; 16(10):2223-2233. PubMed ID: 28729397
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
Ramírez-Moya J; Wert-Lamas L; Santisteban P
Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
20. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.
Ellis BC; Graham LD; Molloy PL
Biochim Biophys Acta; 2014 Feb; 1843(2):372-86. PubMed ID: 24184209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
